Dose and administration for suppressing cardiotoxicity in treatment with ERBB2 targeted immunoliposomes containing anthracycline chemotherapeutic agents

摘要

Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.